Non-Antibiotic Antimicrobial for Treatment of Respiratory Infections
A suite of antimicrobials with a novel mechanism of action to treat COVID-19 associated secondary infections
- The underlying technologies are protected by a suite of patent families. These include granted patents in several jurisdictions (EPO, China, Australia, New Zealand), with pending applications in several other jurisdictions, including US and Japan.
- Patent application submitted
- Development partner